{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:14:37Z","timestamp":1791432877802,"version":"4.3.3"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background: Acute transverse myelitis (ATM) is an inflammatory disorder of the spinal cord with heterogeneous etiologies, including autoimmune, infectious, paraneoplastic, and drug-induced causes. Tumor necrosis factor-alpha (TNF-\u03b1) inhibitors have been infrequently associated with inflammatory central nervous system events, including transverse myelitis. TNF-inhibitor-associated myelitis typically presents with short-segment lesions, a normal brain MRI, and partial responsiveness to corticosteroids. Longitudinally extensive transverse myelitis (LETM) and steroid-refractory cases are uncommon. Case Presentation: A 39-year-old woman with psoriatic arthritis treated with etanercept for two years presented with subacute progressive bilateral lower-extremity sensory loss and weakness. MRI revealed a T2 hyperintense spinal cord lesion extending from T11 to L1 with gadolinium enhancement, consistent with transverse myelitis, while brain MRI was normal. Cerebrospinal fluid analysis showed lymphocytic pleocytosis, elevated protein, oligoclonal bands, and increased kappa free light chains. Extensive infectious, metabolic, paraneoplastic, and autoimmune testing, including aquaporin-4 and MOG antibodies, was negative. Despite high-dose intravenous corticosteroids and the discontinuation of etanercept, the patient experienced clinical worsening with lesion expansion, meeting criteria for LETM, and developed urinary retention. She subsequently underwent plasma exchange, resulting in radiologic improvement and moderate clinical recovery. Conclusions: This case highlights an atypical presentation of TNF-inhibitor-associated myelitis characterized by a biphasic course, longitudinally extensive spinal cord involvement, steroid refractoriness, and responsiveness to plasma exchange. These features suggest either an unusually severe TNF-inhibitor-related inflammatory phenotype or a TNF-inhibitor-triggered antibody-mediated demyelinating process. Reports of TNF-inhibitor-associated myelitis evolving into longitudinally extensive, steroid-refractory disease remain limited, and this presentation may broaden the recognized clinical spectrum of TNF-\u03b1-related CNS inflammatory events. Close neurologic follow-up and heightened awareness of severe CNS complications associated with TNF-\u03b1 inhibitors are warranted.<\/jats:p>","DOI":"10.3390\/clinpract16050086","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:32:22Z","timestamp":1777469542000},"page":"86","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Steroid Refractory and Plasma Exchange Partially Responsive Longitudinally Extensive Transverse Myelitis Due to Tumor Necrosis Factor-Alpha (Etanercept): A Case Report"],"prefix":"10.3390","volume":"16","author":[{"given":"Jelena","family":"Stojsavljevic","sequence":"first","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael R.","family":"Perez","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"},{"name":"Department of Neurology, Mayo Clinic Health System, Eau Claire, WI 54703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Petcu","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine","family":"Odenigbo","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Madrid","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5312-8812","authenticated-orcid":false,"given":"Igor","family":"Dumic","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3012-4560","authenticated-orcid":false,"given":"Charles W.","family":"Nordstrom","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI 54703, USA"},{"name":"Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14737175.2023.2195095","article-title":"Current perspectives on the diagnosis and management of acute transverse myelitis","volume":"23","author":"Tisavipat","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"ref_2","first-page":"62","article-title":"Myelitis and Other Autoimmune Myelopathies","volume":"27","author":"Flanagan","year":"2021","journal-title":"Contin. (Minneap. Minn.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1212\/NXI.0000000000001071","article-title":"Modern Look at Transverse Myelitis and Inflammatory Myelopathy: Epidemiology of the National Veterans Health Administration Population","volume":"8","author":"Abbatemarco","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS Demyelination with TNF-\u03b1 Blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e200472","DOI":"10.1212\/NXI.0000000000200472","article-title":"Incidence, Etiology, and Long-Term Outcome of Acute Myelitis in Stockholm County, Sweden: A Population-Based Study","volume":"12","author":"Jonsson","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gritsch, D., and Valencia-Sanchez, C. (2022). Drug-related immune-mediated myelopathies. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1003270"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0961203309345730","article-title":"Transverse myelitis and vaccines: A multi-analysis","volume":"18","author":"Kivity","year":"2009","journal-title":"Lupus"},{"key":"ref_8","first-page":"20552173211070750","article-title":"Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor","volume":"8","author":"Chey","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109031","DOI":"10.1016\/j.clineuro.2025.109031","article-title":"Longitudinally extensive transverse myelitis associated with long-term adalimumab therapy: A diagnostic challenge","volume":"256","author":"Roa","year":"2025","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jns.2017.01.023","article-title":"TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders","volume":"373","author":"Barreras","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","article-title":"Etanercept and demyelinating disease in a patient with psoriasis","volume":"54","author":"Sukal","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e39012","DOI":"10.1097\/MD.0000000000039012","article-title":"Safety of TNF-\u03b1 inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database","volume":"103","author":"Zheng","year":"2024","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, M., You, R., Su, Y., Zhou, H., and Gong, S. (2023). Characteristic analysis of adverse reactions of five anti-TNF\u0251 agents: A descriptive analysis from WHO-VigiAccess. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1169327"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor\u2013Inhibitor Treatment for Autoimmune Diseases: A Systematic Review and Meta-Analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: A French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"key":"ref_16","first-page":"e558","article-title":"Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor \u03b1 in 4 Canadian Provinces: A Population-Based Study","volume":"100","author":"Li","year":"2023","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"577587","DOI":"10.1016\/j.jneuroim.2021.577587","article-title":"CNS demyelination with TNF\u03b1 inhibitor exposure: A retrospective cohort study","volume":"356","author":"Hutto","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gough, P., and Myles, I.A. (2020). Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.585880"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408363.2022.2039591","article-title":"Oligoclonal bands: Clinical utility and interpretation cues","volume":"59","author":"Carta","year":"2022","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_21","unstructured":"Expert Panel on Neurologic Imaging, Kalnins, A., Lewis, L.M., Soderlund, K.A., Austin, M.J., Chu, S., Hawley, D.B., Kontzialis, M., Levy, M., and McMenamy, J. (2026). ACR Appropriateness Criteria\u00ae Demyelinating Diseases. J. Am. Coll. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00479","DOI":"10.1016\/j.idcr.2018.e00479","article-title":"Acute transverse myelitis-A rare clinical manifestation of Lyme neuroborreliosis","volume":"15","author":"Dumic","year":"2018","journal-title":"IDCases"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e929952","DOI":"10.12659\/AJCR.929952","article-title":"\u201cDouble Trouble\u201d: Severe Meningoencephalitis Due to Borrelia burgdorferi and Powassan Virus Co-Infection Successfully Treated with Intravenous Immunoglobulin","volume":"22","author":"Dumic","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/idr15040035","article-title":"Anaplasma phagocytophilum Encephalitis: A Case Report and Literature Review of Neurologic Manifestations of Anaplasmosis","volume":"15","author":"Cosiquien","year":"2023","journal-title":"Infect. Dis. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.rdc.2017.06.005","article-title":"Neurologic Manifestations of Rheumatoid Arthritis","volume":"43","author":"DeQuattro","year":"2017","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.24582","article-title":"Discriminating Long Myelitis of Neuromyelitis Optica From Sarcoidosis","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/5\/86\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:26:15Z","timestamp":1777472775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/5\/86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["clinpract16050086"],"URL":"https:\/\/doi.org\/10.3390\/clinpract16050086","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}